Melinda Day Takematsu v. Takeda Pharmaceuticals U.S.A., Inc.

District Court, D. New Jersey·Decided August 14, 2026·No. 2:22-cv-06650·Unknown

Opinion

NOT FOR PUBLICATION UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY MELINDA DAY TAKEMATSU, No. 22-cv-6650 Plaintiff, v. OPINION & ORDER TAKEDA PHARMACEUTICALS U.S.A., INC., Defendant. CECCHI, District Judge. Before the Court is defendant Takeda Pharmaceuticals U.S.A., Inc.’s (“Takeda” or “Defendant”) motion for summary judgment, ECF No. 64; see ECF No. 65 (“Def.’s MSJ Br.”), and plaintiff Melinda Day Takematsu’s (“Plaintiff”) cross-motion for partial summary judgment, ECF No. 67; see ECF No. 68 (“Pl.’s Opp’n & Cross-MSJ Br.”). Takeda opposed Plaintiff’s cross- motion and replied in further support of its motion, ECF No. 71 (“Def.’s Opp’n & Reply Br.”), and Plaintiff filed a reply in support of her cross-motion, ECF No. 73 (“Pl.’s Reply Br.”). The Court decides the motions without oral argument. Fed. R. Civ. P. 78(b); L. Civ. R. 78.1(b). For the reasons set forth below, the Court will grant in part and deny in part Takeda’s motion for summary judgment and deny Plaintiff’s cross-motion for summary judgment. I. BACKGROUND1 This matter arises out of Plaintiff’s employment at Takeda, a large pharmaceutical company, and concerns Takeda’s alleged failure to administer Plaintiff’s disability accommodations and subsequent transfer of Plaintiff to another role. 1 Background facts come from the pleadings, evidence, the parties’ statements of undisputed material facts pursuant to Local Civil Rule 56.1, the parties’ counterstatements thereto, and the parties’ replies to those counterstatements. See ECF Nos. 66 (“Def.’s SMF”), 69 (“Pl.’s SMF”), A. Plaintiff’s Disability Accommodations Plaintiff began working for Takeda in 2018, when Takeda merged with Plaintiff’s previous employer. Pl.’s SMF ¶ 4. Prior to the merger, Plaintiff was an associate director of sales, id. ¶ 3, and shortly after the merger, Takeda elevated her to Senior Regional Business Director (“SRBD”) in charge of managing seven Northeast-based sales representatives in the area of Hereditary

Angioedema, Def.’s SMF ¶¶ 5–6. As an SRBD, Plaintiff was “expected to lead, manage, provide observational coaching for, and develop the skills of” the sales representatives on her team. Id. ¶ 6. She was also responsible for developing and presenting business plans and reviews. ECF No. 65-7 (“Potilechio Dep.”) at 50:16–22, 56:1–12; Def.’s SMF ¶ 15; Pl.’s CSMF ¶ 15; ECF No. 65- 28 at 2. In March 2018, Plaintiff began experiencing symptoms of her then-undiagnosed Multiple Sclerosis (“MS”), such as slurred speech, confusion, forgetting words, and dizziness—all of which were triggered and exacerbated by stressful situations. Def.’s SMF ¶ 11; Pl.’s SMF ¶ 8. Nonetheless, Plaintiff continued to work as an SRBD. For instance, in her 2019 performance

review, Plaintiff’s superiors noted that Plaintiff was “dedicated to” “elevating her existing skill set” and “continue[d] to make progress in her leadership journey.” ECF No. 65-39 at 3; see also ECF No. 65-18; Pl.’s SMF ¶ 10 (“[A] fellow SRBD . . . note[d] [in a text message to Plaintiff] that . . . [she] was doing an ‘outstanding job.’”). At the same time, despite a “strong” fourth quarter, Plaintiff’s sales team ranked last for the 2019 performance year, Def.’s SMF ¶ 30; Pl.’s SMF ¶ 11, and her supervisors commented that Plaintiff needed to “[c]ontinue [her] transition from

70 (“Pl.’s CSMF”), 71-4 (“Def.’s Reply to Pl.’s CSMF”), 72 (“Def.’s CSMF”), 73-1 (“Pl.’s Reply to Def.’s CSMF”). [an] [i]ndividual [c]ontributor” to a “leader” and “lack[ed] confidence in . . . presenting [and] recruiting,” ECF No. 65-39 at 2–3; see ECF No. 65-18 at 2–3; Def.’s SMF ¶¶ 30–34. In September 2020, Plaintiff was diagnosed with MS and began a course of treatment. Pl.’s SMF ¶ 9. Plaintiff informed Manny Gaspar (“Gaspar”), her then-manager and head of sales for Plaintiff’s division, and several other colleagues of her diagnosis. Def.’s SMF ¶¶ 8, 11. Initially,

Plaintiff continued in her SRBD role full-time during treatment, and her sales team ranked second (out of five) in terms of total sales for fiscal year 2020. Pl.’s SMF ¶¶ 10–11; Def.’s CSMF ¶ 11. However, on January 24, 2021, Plaintiff began short-term disability leave to “take . . . time to focus on [her] health and to focus on living [her] new normal.” ECF No. 65-3 (“Takematsu Dep.”) at 94:1–8; see Pl.’s SMF ¶ 12; Def.’s CSMF ¶ 12. During her leave, Plaintiff continued to experience “dizziness, fatigue, slurring of her words, confusion[,] . . . memory issues,” and balance issues. Pl.’s SMF ¶ 13. On April 5, 2021, with the end of her leave approaching, Plaintiff obtained a letter from her psychologists at New York University. Def.’s SMF ¶ 13; see also Takematsu Dep. at 97:7–

99:6. In the letter (the “NYU Letter”), Plaintiff’s psychologists made several “clinical[] recommend[ations]” related to her return to work, including: (i) “advanced and extended preparation time for presentations” and “plan documents” (the “Advance Preparation Accommodation”), (ii) “previews [of] expected questions” in advance of presentations, as well as “extended and advanced review” of those questions (the “Question Preview Accommodation”), (iii)“additional reviews with management” to ensure her understanding of work assignments (the “Management Review Accommodation”), and (iv) the use of assists (e.g., cue cards, scripts) during presentations (the “Presentation Assists Accommodation”) (collectively, the “Approved Accommodations”).2 ECF No. 65-10; see Pl.’s SMF ¶ 14; Def.’s SMF ¶ 13. Plaintiff submitted the NYU Letter to Takeda, requesting that it approve her psychologists’ recommendations as disability accommodations upon her return to work. Pl.’s SMF ¶ 14. After a conversation between human resources partner Susan Potilechio (“Potilechio”) and Plaintiff, as well as discussions between Takeda’s human resources staff and Gaspar related to the feasibility of certain

accommodations, Takeda and Plaintiff agreed to the Approved Accommodations. Id. ¶¶ 15–16; Def.’s SMF ¶¶ 14–16. In addition, Plaintiff states that she requested and Takeda approved one additional accommodation not listed in the NYU Letter: the opportunity to make presentations to her manager prior to presenting live in front of a group (the “Mock Presentation Accommodation”). Pl.’s SMF ¶ 16. As discussed further below, Takeda disputes Plaintiff’s account and there is conflicting evidence on this point. Compare, e.g., id., with Def.’s CSMF ¶ 16. Plaintiff returned to work on April 18, 2021, with Gaspar aware of her Approved Accommodations. Def.’s SMF ¶¶ 12, 15; ECF No. 65-5 (“Gaspar Dep.”) at 29:18–36:20. Initially,

Takeda generally complied with the Approved Accommodations. For instance, Gaspar met with Plaintiff weekly, whereas he met with other SRBDs every other week. Def.’s SMF ¶ 15; Pl.’s CSMF ¶ 15. He also set aside additional time to review Plaintiff’s quarterly business reviews with

Free access — add to your briefcase to read the full text and ask questions with AI

Melinda Day Takematsu v. Takeda Pharmaceuticals U.S.A., Inc., (D.N.J. 2026).

Melinda Day Takematsu v. Takeda Pharmaceuticals U.S.A., Inc. (Melinda Day Takematsu v. Takeda Pharmaceuticals U.S.A., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Reedy v. Evanson
615 F.3d 197 (Third Circuit, 2010)
Ray v. Pinnacle Health Hospitals, Inc.
416 F. App'x 157 (Third Circuit, 2010)
McKenna v. City of Philadelphia
649 F.3d 171 (Third Circuit, 2011)
Gray v. York Newspapers, Inc.
957 F.2d 1070 (Third Circuit, 1992)
Katherine L. Taylor v. Phoenixville School District
184 F.3d 296 (Third Circuit, 1999)
Janet M. Turner v. Hershey Chocolate USA
440 F.3d 604 (Third Circuit, 2006)
Colwell v. Rite Aid Corp.
602 F.3d 495 (Third Circuit, 2010)
Pignataro v. Port Auth. of New York and New Jersey
593 F.3d 265 (Third Circuit, 2010)
Pichler v. UNITE
542 F.3d 380 (Third Circuit, 2008)
Skerski v. Time Warner Cable Co.
257 F.3d 273 (Third Circuit, 2001)
Whelan v. Teledyne Metalworking Products
226 F. App'x 141 (Third Circuit, 2007)
Green v. Brennan
578 U.S. 547 (Supreme Court, 2016)